NEW YORK--(BUSINESS WIRE)--Abraham, Fruchter & Twersky, LLP has filed a securities fraud class action against Aeterna Zentaris Inc. (“Aeterna Zentaris” or the “Company”) (NASDAQ:AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the “Court”).
The case alleges that the defendants made materially false or misleading statements with respect to the safety and efficacy of the Company’s drug Macrilen™. A November 6, 2014, press release by the Company brought these facts to light by announcing that the FDA had issued a Complete Response Letter refusing to approve the Company’s New Drug Application because of “the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.”
The lawsuit is brought on behalf of a class (the “Class”) of investors who purchased shares of Aeterna Zentaris between and including June 26, 2012 and November 5, 2014 (the “Class Period”). If you are a member of the Class and wish to serve as a lead plaintiff, then you must move the Court no later than January 12, 2015. You are, however, under no obligation to move for appointment as lead plaintiff.
If you would like to discuss this investigation, or if you have any questions concerning your rights as a potential lead plaintiff, you may contact: Jeffrey S. Abraham or Philip T. Taylor of Abraham, Fruchter & Twersky, LLP toll free at (800) 440-8986, or via e-mail at email@example.com or firstname.lastname@example.org.
Abraham, Fruchter & Twersky, LLP, which is based in New York and has an office in California, has extensive experience in shareholder and securities class action cases, and the firm has been ranked among the leading class action law firms in terms of recoveries achieved by a survey of class action law firms conducted by Institutional Shareholder Services.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.